The company withdrew its draft prospectus for the IPO in November 2008 after the global financial crisis rocked the investment climate the world over.

'Our four strategic business units will be run as independent profit centres with dedicated teams. We also plan to monetise products, which are in the pipeline, by launching them in the market. With an integrated systems biology platform, Avesthagen focuses on achieving convergence of food, pharma and population genetics for predictive, preventive and personalised healthcare.